Literature DB >> 769706

Phenylbutazone and chromosomal damage.

S Walker, A Price Evans, P A Benn, T R Littler, L D Halliday.   

Abstract

Investigation of 44 paired test and control patients, all suffering from rheumatoid arthritis, following exposure to phenylbutazone (PBZ) and/or oxyphenbutazone (OPB), suggests that there is no significant increase in the level of chromosomal damage in lymphocytes. The control subjects comprised two series, one previously exposed to PBZ and/or OPB, but not for at least 1-5 years, and the other never exposed to PBZ or OPB. No significant difference in the level of chromosome damage was found between patients never exposed, previously exposed, or now receiving PBZ and/or OPB.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 769706      PMCID: PMC1006441          DOI: 10.1136/ard.34.5.409

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  4 in total

1.  MICROTECHNIQUE FOR CULTURING LEUKOCYTES FROM WHOLE BLOOD.

Authors:  D T ARAKAKI; R S SPARKES
Journal:  Cytogenetics       Date:  1963

2.  Chromosomal studies in patients taking phenylbutazone.

Authors:  A C Stevenson; J Bedford; A G Hill; H F Hill
Journal:  Ann Rheum Dis       Date:  1971-09       Impact factor: 19.103

3.  [Cytogenetic effect of phenylbutazone in human lymphocytes in vitro].

Authors:  H F Wissmüller
Journal:  Arzneimittelforschung       Date:  1971-11

4.  The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material.

Authors:  J J BURNS; R K ROSE; T CHENKIN; A GOLDMAN; A SCHULERT; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1953-11       Impact factor: 4.030

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.